PTC Therapeutics Inc banner

PTC Therapeutics Inc
SWB:BH3

Watchlist Manager
PTC Therapeutics Inc Logo
PTC Therapeutics Inc
SWB:BH3
Watchlist
Price: 54.28 EUR -3.28%
Market Cap: €4.1B

Wall St Price Targets

BH3 Price Targets Summary
PTC Therapeutics Inc

Wall Street analysts forecast BH3 stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for BH3 is 83.59 EUR with a low forecast of 57.67 EUR and a high forecast of 114.38 EUR.

Lowest Forecast
Price Target
57.67 EUR
6% Upside
Average Forecast
Price Target
83.59 EUR
54% Upside
Highest Forecast
Price Target
114.38 EUR
111% Upside
PTC Therapeutics Inc Competitors:
Price Targets
NWSA
News Corp
37% Upside
WLFC
Willis Lease Finance Corp
1% Upside
BRI
Britania PCL
13% Upside
INO
Inovio Pharmaceuticals Inc
207% Upside

Revenue
Forecast

35% / Year
Past Growth
-2% / Year
Estimated Growth
Estimates Accuracy
-2%
Average Miss
35% / Year
Past Growth
-2% / Year
Estimated Growth
Estimates Accuracy
-2%
Average Miss

Over the last 13 years, the compound annual growth rate for Revenue has been 35%. The projected CAGR for the next 3 years is -2%.

Gross Profit
Forecast

N/A
Past Growth
-5% / Year
Estimated Growth
Estimates Accuracy
1%
Average Beat
N/A
Past Growth
-5% / Year
Estimated Growth
Estimates Accuracy
1%
Average Beat

The compound annual growth rate for Gross Profit over the next 3 years is -5%.

Operating Income
Forecast

N/A
Past Growth
-12% / Year
Estimated Growth
Estimates Accuracy
3%
Average Beat
N/A
Past Growth
-12% / Year
Estimated Growth
Estimates Accuracy
3%
Average Beat

The compound annual growth rate for Operating Income over the next 3 years is -12%.

Pre-Tax Income
Forecast

N/A
Past Growth
-20% / Year
Estimated Growth
Estimates Accuracy
8%
Average Beat
N/A
Past Growth
-20% / Year
Estimated Growth
Estimates Accuracy
8%
Average Beat

The compound annual growth rate for Pre-Tax Income over the next 3 years is -20%.

Net Income
Forecast

70% / Year
Past Growth
-20% / Year
Estimated Growth
Estimates Accuracy
5%
Average Beat
70% / Year
Past Growth
-20% / Year
Estimated Growth
Estimates Accuracy
5%
Average Beat

Over the last 13 years, the compound annual growth rate for Net Income has been 70%. The projected CAGR for the next 3 years is -20%.

Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.

What is BH3's stock price target?
Price Target
83.59 EUR

According to Wall Street analysts, the average 1-year price target for BH3 is 83.59 EUR with a low forecast of 57.67 EUR and a high forecast of 114.38 EUR.

What is the Revenue forecast for PTC Therapeutics Inc?
Projected CAGR
-2%

Over the last 13 years, the compound annual growth rate for Revenue has been 35%. The projected CAGR for the next 3 years is -2%.

What is the Gross Profit forecast for PTC Therapeutics Inc?
Projected CAGR
-5%

The compound annual growth rate for Gross Profit over the next 3 years is -5%.

What is the Operating Income forecast for PTC Therapeutics Inc?
Projected CAGR
-12%

The compound annual growth rate for Operating Income over the next 3 years is -12%.

What is the Pre-Tax Income forecast for PTC Therapeutics Inc?
Projected CAGR
-20%

The compound annual growth rate for Pre-Tax Income over the next 3 years is -20%.

What is the Net Income forecast for PTC Therapeutics Inc?
Projected CAGR
-20%

Over the last 13 years, the compound annual growth rate for Net Income has been 70%. The projected CAGR for the next 3 years is -20%.

Back to Top
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett